Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in AR-V7 Positive mCRPC
NCT03050866Phase 2Unknown
- Sponsor
- Erasmus MC
- Start
- Feb 2017
- Primary completion
- Jan 2022
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Erasmus MC. Status: unknown.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03050866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050866.